Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
|
|
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
|
Add to portfolio |
|
|
|
| Price: |
$173.91
| | Metrics |
| OS: |
125.0
|
M
| |
|
|
| Market cap: |
$21.7
|
B
| |
|
|
|
Net cash:
|
$1.01
|
B
| |
$8.09
|
per share
|
|
EV:
|
$20.7
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 1,037.4 | 844.3 | 492.9 | 219.8 | 74.9 | 89.9 | 47.2 | 41.1 |
| Revenue growth | 22.9% | 71.3% | 124.3% | 193.4% | -16.7% | 90.7% | 14.8% | -18.7% |
| Cost of goods sold | 140.2 | 115.0 | 74.2 | 25.1 | 1.8 | 0.0 | 0.0 | 0.0 |
| Gross profit | 897.2 | 729.3 | 418.7 | 194.7 | 73.1 | 89.9 | 47.2 | 41.1 |
| Gross margin | 86.5% | 86.4% | 84.9% | 88.6% | 97.6% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 770.7 | 620.6 | 588.4 | 479.0 | 382.4 | 199.4 | 89.4 | |
| Research and development | 883.0 | 792.2 | 654.8 | 655.1 | 505.4 | 390.6 | 382.4 | 276.5 |
| General and administrative | | | | | | | | 60.6 |
| EBIT | -785.1 | -708.7 | -828.4 | -939.4 | -804.7 | -500.1 | -424.6 | -296.0 |
| EBIT margin | -75.7% | -83.9% | -168.1% | -427.5% | -1074.2% | -556.2% | -900.3% | -720.3% |
| Pre-tax income | -1,127.0 | -852.1 | -855.6 | -885.3 | -760.7 | -490.9 | -410.1 | -290.1 |
| Income taxes | 4.2 | 0.7 | 2.7 | 0.9 | 0.8 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | | | 0.0% | 0.0% | 0.0% |
| Net income | -1,131.2 | -852.8 | -858.3 | -886.1 | -761.5 | -490.9 | -410.1 | -290.1 |
| Net margin | -109.0% | -101.0% | -174.1% | -403.2% | -1016.6% | -545.9% | -869.6% | -705.8% |
| |
| Diluted EPS | ($9.30) | ($7.20) | ($7.46) | ($8.11) | ($7.57) | ($5.42) | ($4.79) | ($3.45) |
| Shares outstanding (diluted) | 121.7 | 118.5 | 115.0 | 109.3 | 100.6 | 90.6 | 85.6 | 84.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|